Biochemical diagnosis and localization of pheochromocytoma: Can we reach a consensus?

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 332-347

  Grossman, Ashley ^a   Pacak, Karel ^b   Sawka, Anna ^c   Lenders, Jacques W M ^d   Harlander, Debra ^e   Peaston, Robert T ^f   Reznek, Rodney ^a   Sisson, James ^g   Eisenhofer, Graeme ^h  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Pheochromocytoma Support Group   (United States)

^f FREEMAN HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Biochemical diagnosis; Catecholamines; Computed tomography; Localization; Magnetic resonance imaging; Metanephrines; MIBG; Pheochromocytoma; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CATECHOLAMINE; CLONIDINE; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; METADRENALIN; NORMETADRENALIN; PENTETREOTIDE; PENTOLONIUM TARTRATE;

ADRENAL TUMOR; CHEMICAL ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DENSITOMETRY; HUMAN; IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY;

EID: 33750592316     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.038     Document Type: Conference Paper

References (52)

1. PLATTS, J.K., P.J. DREW & J.N. HARVEY. 1995. Death from phaeochromocytoma: lessons from a post-mortem survey. J. Roy. Coll. Physicians Lond. 29: 299-306.
2. LO, C.Y. et al. 2000. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am. J. Surg. 179: 212-215.
3. MCNEIL, A.R. et al. 2000. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust. N. Z. J. Med. 30: 648-652.
4. KALTSAS, G.A., D. PAPADOGIAS & A.B. GROSSMAN. 2004. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front. Horm. Res. 31: 61-75.
5. SJOERDSMA, A. et al. 1959. Studies on the biogenesis and metabolism of norepinephrine in patients with pheochromocytoma. J. Clin. Invest. 38: 31-38.
6. CROUT, J.R. & A. SJOERDSMA. 1964. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J. Clin. Invest. 43: 94-102.
7. EISENHOFER, G. et al. 2003. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr. Pathol. 14: 193-212.
8. EISENHOFER, G. et al. 1999. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N. Engl. J. Med. 340: 1872-1879.
9. RABER, W. et al. 2000. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch. Intern. Med. 160: 2957-2963.
10. LENDERS, J.W. et al. 2002. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434.
11. SAWKA, A.M. et al. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab. 88: 553-558.
12. SAWKA, A.M. et al. 2004. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr. Disord. 4: 2.
13. UNGER, N. et al. 2006. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur. J. Endocrinol. 154: 409-417.
14. GARDET, V. et al. 2001. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J. Hypertens. 19: 1029-1035.
15. GERLO, E.A. & C. SEVENS. 1994. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin. Chem. 40: 250-256.
16. DAVIDSON, D.F. 2002. Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. Ann. Clin. Biochem. 39: 557-566.
17. GULLER, U. et al. 2006. Detecting pheochromocytoma: defining the most sensitive test. Ann. Surg. 243: 102-107.
18. SAWKA, A.M. et al. 2004. The economic implications of three biochemical screening algorithms for pheochromocytoma. J. Clin. Endocrinol. Metab. 89: 2859-2866.
19. BROWN, M.J. & D.J. ALLISON. 1981. Renal conversion of plasma DOPA to urine dopamine. Br. J. Clin. Pharmacol. 12: 251-253.
20. EISENHOFER, G. et al. 2005. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab. 90: 2068-2075.
21. ROSS, G.A. et al. 1993. Plasma and 24 h-urinary catecholamine concentrations in normal and patient populations. Ann. Clin. Biochem. 30 (Pt. 1): 38-44.
22. SAWKA, A.M. et al. 2005. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age? BMC Endocr. Disord. 5: 1.
23. EISENHOFER, G. et al. 1995. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin. Sci. (Lond.) 88: 533-542.
24. EISENHOFER, G. et al. 2003. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88: 2656-2666.
25. BROWN, M.J. et al. 1981. Increased sensitivity and accuracy of phaeochromocytoma diagnosis achieved by use of plasma-adrenaline estimations and a pentolinium-suppression test. Lancet 1: 174-177.
26. BRAVO, E.L. et al. 1981. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N. Engl. J. Med. 305: 623-626.
27. MULINARI, R.A. et al. 1987. The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary metanephrine measurements. Braz. J. Med. Biol. Res. 20: 43-46.
28. NEUMANN, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459-1466.
29. AMAR, L. et al. 2005. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23: 8812-8818.
30. REMINE, W. et al. 1974. Current management of pheochromocytoma. Ann. Surg. 179: 740-748.
31. TRONCONE, L. et al. 1990. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur. J. Nucl. Med. 16: 325-335.
32. PEPPERCORN, P.D., A.B. GROSSMAN & R.H. REZNEK. 1998. Imaging of incidentally discovered adrenal masses. Clin. Endocrinol. (Oxford) 48: 379-388.
33. GRUMBACH, M.M. et al. 2003. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann. Intern. Med. 138: 424-429.
34. EISENHOFER, G. et al. 2005. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin. Chem. 51: 735-744.
35. FRANCIS, I. & M. KOROBKIN. 1996. Pheochromocytoma. Adv. Uroradiol. 34: 1101-1112.
36. GOLDSTEIN, R.E. et al. 1999. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229: 755-764; discussion 764-766.
37. SAHDEV, A. et al. 2005. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur. Radiol. 15: 85-92.
38. MUKHERJEE, J.J. et al. 1997. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202: 227-231.
39. QUINT, L.E. et al. 1987. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 165: 89-93.
40. VARGHESE, J.C. et al. 1997. MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin. Radiol. 52: 603-606.
41. FURUTA, N. et al. 1999. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int. J. Urol. 6: 119-124.
42. ILIAS, I., B. SHULKIN & K. PACAK. 2005. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol. Metab. 16: 66-72.
43. MISKULIN, J. et al. 2003. Is preoperative iodine 123 meta- iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134: 918-922; discussion 922-923.
44. HOEGERLE, S. et al. 2002. Pheochromocytomas: detection with 18F DOPA whole body PET: initial results. Radiology. 222: 507-512.
45. PACAK, K. et al. 2001. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.
46. SHULKIN, B.L. et al. 1999. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl. Med. 212: 35-41.
47. MANN, G.N. et al. 2006. [(11)C]metahydroxyephedrine and [(18)F]Fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann. Surg. Oncol. 13: 187-197.
48. TRAMPAL, C. et al. 2004. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230: 423-428.
49. MEDIAVILLA GARCIA, J.D. et al. 1999. A comparative study of 9 cases of adrenal pheochromocytoma and 11 cases of extra-adrenal pheochromocytoma. Rev. Clin. Esp. 199: 343-348.
50. KALTSAS, G. et al. 2001. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86: 895-902.
51. CHEW, S.L. et al. 1994. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay. Q. J. Med. 87: 49-54.
52. PACAK, K. et al. 2001. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J. Clin. Endocrinol. Metab. 86: 3641-3646.